KMO and Cognitive impairment: Mechanistically, compared to the RC group, the RM group showed an increased KYNA/KYN ratio, and a decreased 3-HK/KYN ratio (p < 0.05) KMO inhibition rectifies the neurotoxic–neuroprotective imbalance in the kynurenine pathway (downregulating the 3-HK/3-HANA ratio and upregulating the KYNA/KYN ratio), thereby decreasing seizures, depressive-like behaviors, and cognitive deficits.